Aclaris Therapeutics Inc (NAS:ACRS)
$ 4.91 +0.11 (+2.29%) Market Cap: 685.75 Mil Enterprise Value: 580.34 Mil PE Ratio: 0 PB Ratio: 4.77 GF Score: 38/100

Aclaris Therapeutics Inc ATI-052 Interim Phase 1a Clinical Trial Results Call Transcript

Jan 6, 2026 / 01:00 PM GMT
Release Date Price: $2.65


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ACRS.OQ - Aclaris Therapeutics Inc
Aclaris Therapeutics Inc ATI-052 Interim Phase 1a Clinical Trial Results Call
Jan 06, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the Clara's ATI 052 clinical trial update conference call. At this time, all participants on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session to ask a question. During the session you will need to press 11 on your telephone. You will then hear automated message advising your hand is raised. Please note that today's conference is being recorded. I will now hand the conference over to your speaker host, Will Roberts, head of communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------------
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot